271. Ankylosing spondylitis Clinical trials / Disease details

Clinical trials : 563 / Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04947579 (ClinicalTrials.gov)	August 25, 2021	23/6/2021	A Study of CC-99677 in Participants With Active Ankylosing Spondylitis	A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects With Active Ankylosing Spondylitis	Spondylitis, Ankylosing	Drug: CC -99677;Other: Placebo	Celgene	NULL	Recruiting	18 Years	65 Years	All	256	Phase 2	United States;Canada;Czechia;Germany;Poland;Romania;Russian Federation;Spain;Turkey
2	EUCTR2019-004108-37-DE (EUCTR)	09/07/2021	18/02/2021	A study to determine how effective and safe the drug CC-99677 is for patients with active Ankylosing Spondylitis	A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of CC-99677 in Subjects with Active Ankylosing Spondylitis	Ankylosing Spondylitis MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylosing spondylitis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Code: CC -99677 60mg Capsule INN or Proposed INN: 146368 Other descriptive name: CC -99677 Product Code: CC -99677 30mg Capsule INN or Proposed INN: 146368 Other descriptive name: CC -99677	Celgene Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	256	Phase 2	United States;Czechia;Canada;Spain;Poland;Romania;Turkey;Russian Federation;Germany